| 3.555 0.005 (0.14%) | 04-06 10:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.44 | 1-year : | 6.36 |
| Resists | First : | 4.65 | Second : | 5.44 |
| Pivot price | 4.13  |
|||
| Supports | First : | 3.38 | Second : | 2.81 |
| MAs | MA(5) : | 3.55 |
MA(20) : | 4.35 |
| MA(100) : | 3.71  |
MA(250) : | 3.86 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.5 |
D(3) : | 10.6 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 8.26 | Low : | 2.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RCKT ] has closed above bottom band by 21.1%. Bollinger Bands are 93.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.69 - 3.72 | 3.72 - 3.73 |
| Low: | 3.44 - 3.47 | 3.47 - 3.49 |
| Close: | 3.52 - 3.55 | 3.55 - 3.59 |
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.
Sun, 05 Apr 2026
RCKT stock jumps over 10% premarket: FDA approves its first gene therapy for rare childhood immune disease - MSN
Fri, 03 Apr 2026
[SC TO-C] ROCKET PHARMACEUTICALS, INC. Tender Offer Communication | RCKT SEC Filing - Form SC TO-C - Stock Titan
Wed, 01 Apr 2026
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Sun, 29 Mar 2026
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI - Yahoo Finance
Fri, 27 Mar 2026
RCKT Stock Jumps Over 10% Premarket: FDA Approves Its First Gene Therapy For Rare Childhood Immune Disease - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 109 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 84.9 (%) |
| Shares Short | 14,690 (K) |
| Shares Short P.Month | 14,460 (K) |
| EPS | -2.01 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.3 % |
| Return on Equity (ttm) | -60.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -190 (M) |
| Levered Free Cash Flow | -105 (M) |
| PE Ratio | -1.79 |
| PEG Ratio | 0 |
| Price to Book value | 1.39 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|